Clinical Research Partners, LLC | Forest Avenue, Richmond, VA
Status and phase
Conditions
Treatments
About
The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to separate vaccines for the protection against influenza and SARS-CoV-2. Influenza and COVID-19 are diseases that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. Giving both influenza and COVID-19 vaccines together against influenza and SARS-CoV-2 could provide great benefits to both patients and caregivers in terms of simple and easy care. Around 8550 participants will be assigned into 1 of 8 vaccination groups (Group A, B, C, D, E, F, G or H) by chance.
Cohort 1: Approximately 450 participants will be assigned by chance to one of the following:
Cohort 2: Approximately 4500 participants will be assigned by chance to one of the following:
Cohort 3: Approximately 3600 participants will be assigned by chance to one of the following:
All participants in cohort 1 and cohort 2 will receive 2 injections and participants in cohort 3 will receive 1 injection as per their assigned study group at Visit 1. The participants will be followed for about 6 months. During this time, researchers will assess safety and the body's reaction to the vaccination over approximately 6 months. This will help understand if the study medicine is safe.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Please refer to the study contact for further eligibility details
Primary purpose
Allocation
Interventional model
Masking
8,798 participants in 8 patient groups
Loading...
Central trial contact
Pfizer CT.gov Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal